Analysis and data insight - Articles - Page 232

Capital concerns: Coronavirus pandemic could shorten cash runways

March 30, 2020

As the coronavirus pandemic rages on, biopharma companies are being forced to respond to multiple challenges that could derail their existing business plans. Already companies are reporting that, in therapeutic indications not involving COVID-19, their ongoing and planned clinical trials are being interrupted or delayed by the pressures now being imposed on global health care systems.

BioWorld Financings Reports: Cancer, neurology, endocrine take 47% of funding in 2019

March 30, 2020

By Karen Carey

A comparison of the last three years puts 2019 on top for having brought the most money into the biopharma industry across 15 key therapeutic markets – a total of $299.78 billion vs. $284.7 billion in 2018 and $201.56 billion in 2017. The analyses includes financings tracked by BioWorld and deals and grants that are within the Cortellis database, all covering therapeutic areas included within the corresponding BioWorld Financings Reports for 2019.

Week in review for March 30, 2020: The world shuts down as countries fight to 'flatten the curve'

March 30, 2020

By Peter Winter

A quick look back at top stories.

Money raised by biopharma: 2020 vs. 2019

March 27, 2020

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Biopharma money raised: Jan. 1-March 26, 2020

March 27, 2020

Year-to-date money raised in public, private and other financings of biopharma companies.

Biopharmaceutical collaborations: February 2020

March 27, 2020

Biopharma licensings, joint ventures and collaborations, including: Achaogen, Advaxis, Aimmune, Aptevo, Aradigm, Astrazeneca, Atreca, Bicycle, Biogen, Caribou, Catalent, Cellectis, Cipla, Clover, Collegium, Curis, Cytodyn, Daewoong, Dyadic, Eisai, Evotec, Eyepoint, Genentech, Glenmark, Grifols, GSK, Hanmi, Hikma, Hollister, Hummingbird, Icagen, Immunos, Innocare, Janssen, Jounce, Karuna, Karyopharm, Kissei, Ligand, Luye, Medivir, Merck, Mylan, Nanostring, Norgine, Noxopharm, Otologic, Paratek, Pfizer, Portola, Probiogen, Redhill, Roche, Sangamo, Sarepta, Tetra, Trianni, Wize, Wockhardt, Wuxi, Xencor, Zeria, Zy.

Illustration of big fish eating three smaller fish

Completed biopharmaceutical mergers & acquisitions: February 2020

March 27, 2020

Completed biopharma M&As, including: Aevi Genomic Medicine, Anika, Arthrosurface, Attenua, Aytu, Cerecor, Coda, Dermira, Eli Lilly, Innovus, Promedior, Pvp, Roche, Takeda.

Collaborations between biopharmaceutical companies and government/nonprofit entities: February 2020

March 27, 2020

Deals between biopharma companies and government or nonprofit entities, including: AB Biotics, ACT Genomics, Active Biotech, Active Motif, Agex, Be Cool, Benevolentai, Berg Pharma, Berkeley Lights, Beroni, Biomarin, Bridge, Cellular Biomedicine, Chugai, Cocrystal, Dianomi, Dyadic, Enochian, Entourage Phytolab, Erytech, Evgen, Exicure, FDA, Gemini, Generex, Genprex, Gibson Oncology, Gilead Sciences, GSK, Innovation, J&J, Medigen, NIH, Novartis, Oncologie, Orgenesis, Sanofi Pasteur, Sapphire, Synspira, Theratechnologies, Toa Eiyo, Tonix, VBL, Venturis, WPD.